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Abstract
A common goal for potential cancer therapies is the identification of differences in protein expression or activity that would
allow for the selective targeting of tumor vs. normal cells. The Ras proto-oncogene family (K-Ras, H-Ras and N-Ras) are
amongst the most frequently mutated genes in human cancers. As a result, there has been substantial effort dedicated to
determining which pathways are activated by Ras signaling and, more importantly, which of these contribute to cancer.
Although the most widely studied Ras-regulated signaling pathway is the Raf/mitogen-activated protein kinase cascade,
previous research in model systems has revealed that the Rac1 GTP-binding protein is also required for Ras-induced
biological responses. However, what have been lacking are rigorous in vivo Rac1 target validation data and a clear
demonstration that in Ras-driven hyperplastic lesions, Rac1 activity is increased. Using a combination of genetically-
modified mouse models that allow for the tissue-selective activation or deletion of signaling molecules and an activation-
state sensitive Rac1 antibody that detects GTP-bound Rac1, we found that Rac1 contributes to K-Ras induced epidermal
papilloma initiation and growth and that Rac1 activity is elevated by oncogenic K-Ras in vivo. Previously, it was not practical
to assess Rac1 activation status in the most commonly used format for clinical tumor specimens, formalin-fixed paraffin
embedded (FFPE) tissues samples. However, this study clearly demonstrates that Rac1 is essential for K-Ras driven epithelial
cell hyperproliferation and that Rac1 activity is elevated in tissues expressing mutant oncogenic K-Ras, while also
characterizing the activation-state specific Rac1-GTP antibody as a probe to examine Rac1 activation status in FFPE samples.
Our findings will facilitate further research on the status of Rac1 activity in human tumors and will help to define the tumor
types of the patient population that could potentially benefit from therapies targeting Rac activation or downstream
effector signaling pathways.
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Introduction
Members of the Rho family of GTP-binding proteins act as
molecular switches, cycling between inactive GDP-bound and
active GTP-bound states [1]. The conversion between these states
is regulated by guanine nucleotide exchange factors (GEFs) that
promote the exchange of GDP for GTP to increase Rho activation
[2], and GTPase-accelerating proteins (GAPs) that increase the
rate of Rho-catalyzed hydrolysis of the bond between b and c PO4
groups in GTP by providing a catalytic ‘‘arginine-finger’’ resulting
in Rho inactivation [3,4]. In their GTP-bound active state,
information is conveyed downstream of Rho family proteins
through interactions with effector proteins whose intrinsic activity,
subcellular localization and/or association in multimeric protein
complexes are altered so as to affect signaling flux [5,6]. Although
best known as central regulators of the actin cytoskeleton and cell
morphology [7], Rho GTPases influence a myriad of additional
biological processes such as cell proliferation via actin-dependent
and actin-independent mechanisms [8]. In contrast to the
relatively frequent incidence of activating mutations in Ras genes
(K-Ras, H-Ras and N-Ras [9]), there are no published reports of
activating Rho mutations in human tumors. However, numerous
lines of research indicate that Rho proteins do indeed contribute to
cancer [5,6,10].
Amongst the Rho family, the most thoroughly-characterized are
RhoA, Rac1 and Cdc42. To some extent this reflects historical
factors and yet in many cases these specific proteins do appear to
be vitally important for a number of functions. Early studies using
in vitro cell culture model systems revealed a contribution of Rac1
to cell cycle regulation [11] and in Ras-mediated transformation
[12,13]. However, given that the reagents used to inhibit
endogenous protein signaling were dominant-negative versions of
Rac1 that are encumbered by concerns about their specificity, the
conclusions of these studies may not be adequately robust [14].
Finally, evidence for a dependence of Ras on Rac1 for biological
functions accompanied by evidence of Ras-induced Rac1
activation in vivo has remained elusive.
Genetically-modified mouse models that allow for the condi-
tional and tissue-selective deletion or activation of specific
signaling proteins are now readily available [15]. In this study,
we made use of a strain of mice containing a mutant K-Ras allele
(K-RasG12D) that can be conditionally activated by Cre-recombi-
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nase mediated excision of a floxed transcription termination (LSL)
cassette [16]. It had previously been shown that K-Ras driven lung
tumors were dependent upon Rac1. However, whether Rac1 was
actually activated by K-Ras or merely necessary at a basal level of
activity for K-Ras induced effects was not determined [17]. By
crossing LSL-K-RasG12D mice with those expressing a Cre-estrogen
receptor (Cre:ER) fusion protein under the transcriptional
regulation of the Cytokeratin 14 (K14) promoter, mutant K-
RasG12D expression was induced in murine skin, which resulted in
highly penetrant and rapid development of benign hyperplastic
oral papillomas. Using a conformation sensitive monoclonal
antibody specific for the GTP-bound form of Rac1, we found
that these growths had high levels of active Rac1. Genetically
removing one Rac1 allele significantly impaired K-Ras induced
oral papilloma growth and promoted survival while reducing levels
of active Rac1 within the papillomas. These data demonstrate that
there is a general dependence of K-Ras on Rac1 to drive proliferation
in epithelial tissues in vivo and reveal that this requirement is a
reflection of Rac activation by K-Ras. Given that inhibitors are being
developed to target Rac effector proteins such as PAK kinases [18,19]
or to block Rac activation [20], these results provide compelling
target validation of Rac1 in Ras-driven cancers.
Results
Mice carrying a LSL-K-RasG12D allele on a K14-Cre:ER
background develop hyperplastic oral papillomas
In order to generate a model of Ras-driven skin tumorigenesis, we
crossed LSL-K-RasG12D mice onto a K14-Cre:ER background. We
anticipated that localized activation of the Cre:ER recombinase by
topical application of 4 hydoxytamoxifen (4HT) would result in the
genetic recombination event that would remove the transcriptional
stop sequence, resulting in expression of the K-Ras mutant G12D
allele and ultimately leading to Ras-driven papillomas that would
progress to form epidermal carcinomas. However within two weeks
of birth, mice heterozygous for the LSL-K-RasG12D allele and
containing the K14-Cre:ER transgene spontaneously developed oral
papillomas in the absence of 4HT, suggesting that the Cre:ER fusion
protein was not strictly repressed in the absence of ligand (Figure 1A
upper panel). On rare occasions, growths were manifested at
additional sites such as the side of the head (Figure 1A lower panel
and Table 1). Histological analysis of the papillomas revealed that
they were well differentiated, papillary and hyperplastic, and Ki-67
staining indicated that they developed by hyperproliferation of the
epidermis (Figure 1B). No evidence of invasion or metastases was
observed at necropsy or by histology. Every papilloma analyzed (13/
13) by a PCR specific for the intact LSL cassette showed spontaneous
loss of the LSL cassette that had been knocked into the K-Ras locus
[16], consistent with Cre-mediated recombination and expression of
K-RasG12D (Figure 1C). Residual LSL amplicon observed within
papillomas is likely the result of stromal cells or inflammatory
infiltrate, which are unlikely to exhibit K14-driven Cre-mediated
recombination. The large oral papillomas interfered with feeding
and LSL-K-RasG12D;K14-Cre:ER mice did not thrive (Figure 1D).
Mice developing oral papillomas were sacrificed when their
bodyweight dropped to 80% of that of unaffected littermates.
Compared to LSL-K-RasG12D mice, which survive well into
adulthood, LSL-K-RasG12D;K14-Cre:ER mice exhibited an abbrevi-
ated lifespan, with a median age of just 51 days (Figure 1D).
K-Ras driven tumorigenesis is dependent on Active Rac1
It was reported previously that Rac1 was required for K-
RasG12D-induced lung cancer [17]. Therefore, we sought to
determine whether there was a more general requirement for Rac
activity in K-Ras mediated epithelial tumorigenesis. LSL-K-
RasG12D;K14-Cre:ER mice were crossed onto a background lacking
one allele of Rac1 [21], which allows for normal birth,
development and survival for the duration of the experiment,
with no evident abnormalities observed at necropsy (Figure 2B and
data not shown). On the Rac1Wt/- background, LSL-K-
RasG12D;K14-Cre:ER mice exhibited dramatically smaller oral
papilloma growths and an extended median lifespan of 75 days,
representing a ,50% increase in survival, indicative of slower
growing oral papillomas (Figure 2B). Consistent with reduced
proliferation being a factor in the LSL-K-RasG12D;K14-Cre:ER;
Rac1Wt/- mice, Ki-67 staining in tumours was markedly reduced
compared to those observed from LSL-K-RasG12D;K14-Cre:ER mice
(Figure 2C). These observations indicate that Rac1 contributes to
K-Ras mediated epidermal papillomagenesis.
Rac1 activation by oncogenic K-Ras in vivo
Although the requirement for Rac1 in Ras-induced oncogenic
transformation has been previously reported [12,17], there has
been no prior demonstration that mutant active Ras increases
Rac1 activity in tumors. To this end, we characterized a new
commercially available antibody reported to be specific for the
active GTP-bound state of Rac1. Using this antibody, we were
able to immunoprecipitate active Rac1 in a quantitative way from
NIH 3T3 cells that had been treated with PDGF over varying time
periods (Figure 3A). In the same lysates, total Rac1 levels remained
relatively constant (Figure 3A). We also observed that the
immunofluorescence signal from this antibody increased with the
duration of PDGF treatment in NIH 3T3 cells (Intensity
quantification over 5 fields at Figure 3B and representative fields
at Figure 3C). We therefore concluded that this antibody would be
Figure 1. Spontaneous development of papillomas in mice carrying a LSL-K-RasG12D allele on a K14-Cre:ER background. (A) Within
weeks of birth LSL-K-RasG12D;K14-Cre:ER mice developed papillomas, predominantly in the oral epithelium (upper panel, 78 of 78 mice observed) and
occasionally at additional sites such as the side of the head (lower panel, see Table 1 for incidence). (B) Hematoxylin and eosin staining (H&E) of oral
epithelium shows typical staining in LSL-K-RasG12D mice (upper panel) and large intensely staining growths in LSL-K-RasG12D;K14-Cre:ER mice (lower
panels). Staining for the proliferation marker Ki-67 revealed low levels in LSL-K-RasG12D but elevated levels in the proximal regions of papillomas from
LSL-K-RasG12D;K14-Cre mice. (C) Genotyping of genomic DNA from isolated oral papillomas using a wildtype-allele specific primer pair (Wt) and floxed
transcription termination cassette-specific primer pair (LSL) showed a reduction in the abundance of LSL amplicon within four independent
papillomas (upper panel). This was confirmed by qPCR using the same primer pairs (lower panel). (D) Kaplan-Meier survival curve of LSL-K-RasG12D and
LSL-K-RasG12D;K14-Cre:ER mice shows the dramatic differences between each mouse strain. Median survival for LSL-K-RasG12D;K14-Cre:ER mice was
determined to be 51 days.
doi:10.1371/journal.pone.0017143.g001
Table 1. Incidence of oral and other papillomas in K-
RasG12D;K14-Cre:ER mice.
Incidence of Oral papilloma Other papilloma manifestations
Side of head Urinary Anal
78/78 4/78 9/78 7/78
doi:10.1371/journal.pone.0017143.t001
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useful in determining whether Rac activation occurred in K-Ras-
induced tumors. Immunohistochemical analysis of tumors from
LSL-K-RasG12D;K14-Cre:ER mice showed levels of total Rac1
comparable to those observed in healthy normal oral epithelium
(Figure 3D). In contrast, the level of active GTP-bound Rac was
dramatically increased in K-Ras tumors relative to that in normal
oral epithelium (Figure 3D). In all cases of LSL-K-RasG12D;K14-
Cre:ER tumors (.50), we observed a correlative activation of Rac1.
Staining was reduced in sections from comparably sized tumors
derived from LSL-K-RasG12D;K14-Cre:ER;Rac1Wt/- mice (Figure 3D),
indicating that active Rac1 levels were reduced by deletion of one
Rac1 allele. Therefore, Rac1 activation is a consistent and highly-
reproducible feature of K-Ras activation induced tumorigenesis.
Discussion
The original intent of this study was to create a genetically
modified mouse model in with mutant oncogenic K-RasG12D
would be conditionally expressed following the activation of
Cre:ER protein by topical 4HT administration. However, it
appears that activity of the gene product from the K14-Cre:ER
transgene was insufficiently repressed in the absence of ligand,
resulting in spontaneous deletion of the LSL cassette and
subsequent papilloma development. The effects were likely the
consequence of relatively rare events, with the potency of K-
RasG12D in driving keratinocyte hyperproliferation making each
occurrence abundantly evident.
The link between Ras and Rac was first proposed following
observations that microinjection of recombinant Ras protein
produced membrane ruffles which could be blocked by a form of
Rac1 deficient in GTP binding said to act as a ‘‘dominant-
negative’’ inhibitor [22,23]. The requirement of Rac1 activity for
Ras-mediated oncogenesis was initially reported in 1995 [12,13],
using transformation of NIH 3T3 mouse fibroblasts as the model
system and dominant-negative Rac1 as the inhibitor. Further
support for Ras activation of Rac came from pull-down assays in
which the relatively greater affinity of effector protein Rac-binding
domains (RBD) for GTP-bound over GDP-bound was used to
selectively enrich for active Rac1 from cell lysates [24,25].
Despite the level of interest in the association of Rac activity
with mutant Ras in cancer, there is no data showing that Ras-
driven tumors from either mouse or clinical studies are associated
with elevated Rac1 activity. One reason is that the methods used
to demonstrate Ras-induced Rac activation in vitro (e.g. membrane
Figure 2. Increased survival of LSL-K-RasG12D;K14-Cre:ER mice lacking a Rac1 allele. (A) Macroscopic view of oral papillomas from LSL-K-
RasG12D;K14-Cre:ER (upper panel) and LSL-K-RasG12D;K14-Cre:ER;Rac1Wt/- mice (lower panel). Deficiency for one Rac1 allele dramatically reduced
papilloma growth. (B) Kaplan-Meier survival curve of RacWt/- (n = 20), LSL-K-RasG12D;K14-Cre:ER (n = 78) and LSL-K-RasG12D;K14-Cre:ER;Rac1Wt/- (n = 22)
mice shows the dramatic difference between the two mouse strains. Median survival for LSL-K-RasG12D;K14-Cre:ER;Rac1Wt/- mice was determined to be
75 days, which is 50% greater than the 51 day survival time of LSL-K-RasG12D;K14-Cre:ER mice. (C) Staining for the marker of cell proliferation Ki-67
revealed markedly lower levels in tumors from LSL-K-RasG12D;K14-Cre:ER;Rac1Wt/- mice relative to tumors from LSL-K-RasG12D;K14-Cre:ER+ mice.
doi:10.1371/journal.pone.0017143.g002
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Figure 3. K-Ras activation of Rac in vivo. (A) Active Rac1 was immunoprecipitated from lysates derived from NIH 3T3 cells that had been treated
for the indicated time periods with PDGF (10 ng/ml). Western analysis for Rac1 was carried out on immunoprecipitated protein as well as the original
lysate as indicated. (B) Histogram showing active Rac1 immunofluorescence intensity averaged over 5 fields of NIH 3T3 cells increasing over the
K-Ras Tumorigenesis Requires Rac Activation
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ruffling, pull-downs) cannot be directly converted to use with
FFPE tumor samples. A pull-down reagent comprised of the Pak1-
RBD was used as an affinity probe in immunohistochemistry
experiments to demonstrate Rac activation in FFPE fixed mouse
mammary tumors driven by Neu and TGFb1 [26]. However,
given that there have been few attempts to replicate this method
(e.g. reference [27]), it does not appear to be easily duplicated. As a
result, it would be highly advantageous if a method were
developed to detect active Rac1 in tumors, which could be readily
deployed using standard immunohistochemistry techniques. We
found that an activation-state sensitive Rac1-specific monoclonal
antibody performed as a versatile reagent that could immunopre-
cipitate active Rac1 and detect active Rac1 by immunofluores-
cence in PDGF-stimulated NIH 3T3 fibroblasts. More important-
ly, in FFPE sections this antibody was able to detect increased
active Rac1 in K-Ras driven oral papillomas relative to normal
tissue, which was reduced by the loss of one Rac1 allele.
Interestingly, loss of one Rac1 allele did not reduce Rac1
activation within papillomas by 50%, consistent with the
requirement for a threshold level of Rac1 activation for
papillomagenesis. Our observation that the reduction in Rac1
activation was relatively subtle in RacWt/- tumors compared to
RacWt/Wt tumors, may reflect a positive selection for cells with the
greatest levels of activated Rac. In addition, the reduced tumor
growth may, at least in part, be a consequence of a lower
proportion of cells in the RacWt/- tumors being permissive for K-
Ras driven hyperproliferation, resulting in an apparent lag that
delayed tumor growth. The findings presented in this study could
be used to help define the tumor types and potential patient
population that would benefit from therapies that target Rac
activation or downstream effector signaling pathways.
Materials and Methods
Mice
LSL-K-RasG12D mice were a gift from David Tuveson (Cam-
bridge Research Institute). Mice carrying the Rac1 null allele and
K14-Cre:ER were from Laura Machesky and Owen Sansom. All
procedures were performed under appropriate licenses and
according to the UK Home Office guidelines.
Histological and immunohistochemical procedures
Antibodies used were against active Rac1-GTP (Neweast
Biosciences cat. no.: 26903), Rac1 (Santa Cruz Biotechnology
Inc. cat. no.: sc-217). In both cases, antigen retrieval was carried
out by heating sections of FFPE tissue at 99uC for 20 minutes in
10mM citrate buffer, pH 6.0 followed by blocking in 3% hydrogen
peroxide in phosphate buffered saline (pH 7.0) for 20 minutes and
5% goat serum/PBS for 20 minutes. Incubation with the
appropriate primary antibody was carried out at 4uC overnight
in a humidified atmosphere. Following thorough washing in tap
water, Envision Dual-link-HRP reagent (Dako) was applied and
incubated at room temperature for 1 hour in a humidified
atmosphere. After several rounds of washing in tap water, color
development was carried out using DAB chromogen (Dako). Slides
were counterstained in haematoxylin, dehydrated, cleared and
mounted in DPX (Sigma). Slides were imaged using a Hamamatsu
Nanozoomer NDP slide scanner (Hamamatsu Photonics) and
Digital Slide Server (Slidepath) software.
Immunofluorescence procedures
Cells were fixed in 4% PFA, permeabilised with 0.5% Triton X-
100, and stained in PBS with active Rac1-GTP (Neweast
Biosciences cat. no.: 26903) at 1:500 dilution followed by Alexa
488 fluorophore-conjugated donkey anti–goat antibody (Invitro-
gen) at 1:500 dilution. Filamentous actin structures were stained
with 1:250 dilution of Texas Red–conjugated phalloidin (Molec-
ular Probes). Cover-slips were mounted in Vectashield mounting
medium containing DAPI (Vector Laboratories).
Statistical analysis
Unless indicated, statistical significance was determined by
Student’s t-test. ANOVA was carried out where indicated. In both
cases, P,0.05 was used as the cut-off for significance. Data are
shown as means 6 SD unless otherwise indicated.
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